APA (7th ed.) Citation

GB, C., HM, M., A, G., ME, E., & EV, L. (2025). Sparsentan: A dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy. Expert review of clinical pharmacology, 18(7), 441. https://doi.org/10.1080/17512433.2025.2532659

Chicago Style (17th ed.) Citation

GB, Colbert, Madariaga HM, Gaddy A, Elrggal ME, and Lerma EV. "Sparsentan: A Dual Endothelin and Angiotensin II Receptor Antagonist Approved for IgA Nephropathy." Expert Review of Clinical Pharmacology 18, no. 7 (2025): 441. https://doi.org/10.1080/17512433.2025.2532659.

MLA (9th ed.) Citation

GB, Colbert, et al. "Sparsentan: A Dual Endothelin and Angiotensin II Receptor Antagonist Approved for IgA Nephropathy." Expert Review of Clinical Pharmacology, vol. 18, no. 7, 2025, p. 441, https://doi.org/10.1080/17512433.2025.2532659.